BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

Chinese team provides data for Gilead’s remdesivir against 2019-nCoV  A group from the Chinese Academy of Science’s Wuhan Institute of Virology and the Beijing Institute of Pharmacology and Toxicology showed that remdesivir reduced 2019-nCoV infection...
BC Extra | Aug 2, 2019
Politics & Policy

Stakeholders warn of over-reliance on Chinese APIs

Multiple speakers at a hearing on U.S. use of China biotech supplies this week warned that relying on the country's supplies and services threatens the U.S. drug supply, consumer safety and personal health data. “The...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
BC Extra | May 3, 2019
Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
BioCentury | Mar 9, 2019
Regulation

Gottlieb’s exit interview

FDA Commissioner Scott Gottlieb sat down with BioCentury after announcing his resignation to discuss his approach to promoting medical product innovation, the importance of strategic communications, and how a reorganization will bring FDA drug reviews...
BC Week In Review | Jan 11, 2019
Company News

Former Insys CEO pleads guilty to opioid prescription kickbacks

Michael Babich, former president and CEO of Insys Therapeutics Inc. (NASDAQ:INSY), pleaded guilty on Jan. 9 in conspiring to bribe physicians to unnecessarily prescribe Subsys fentanyl sublingual spray and defraud insurance companies. The opioid is...
BC Week In Review | Aug 10, 2018
Company News

FDA reviewers say data are lacking on TIRF drug use

FDA reviewers pointed to significant data gaps for evaluating the REMS program for transmucosal immediate-release fentanyl (TIRF) drugs at a joint advisory committee meeting Aug. 3. Participants gave "important feedback" that insufficient data exists to...
BioCentury | May 11, 2018
Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline....
BC Extra | Apr 4, 2018
Politics & Policy

NIH, FDA announce opioids plans

At the National Rx Drug Abuse and Heroin Summit on Wednesday, NIH released details on its plans for spending $1.1 billion in FY18 to address the opioid abuse epidemic and FDA described plans for extending...
Items per page:
1 - 10 of 679